Johnson Pharmacare (532154) Q4 21/22 earnings summary

Executive summary

• FY22 revenue was Rs 32.63m and net profit Rs 0.97m; operations remained limited, with management citing scarce working capital and seeking an opportunity to make operations active.

• Statutory auditors issued an unmodified opinion on the standalone financial statements; the secretarial audit identified several listing and filing compliance gaps.

Financial highlights

• Revenue from operations was Rs 32.63m vs Rs 7.60m in FY21; total expenses were Rs 31.29m vs Rs 7.58m.

• Profit before tax was Rs 1.34m; income tax expense was Rs 0.38m and net profit was Rs 0.97m, vs FY21 net profit of Rs 11,742.

• Basic and diluted EPS was Rs 0.02 vs Rs 0.00 in FY21; total comprehensive income was Rs 0.97m.

Outlook and guidance

• Management said future development depends on commencing operations and is seeking a suitable opportunity to make operations active.

• Cost-reduction measures had been undertaken to the extent feasible, with further efforts to operationalize the business.